DOCSLIB.ORG

Ophthalmic Compositions of Parasympathetic Stimulants and Anti

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ophthalmic Compositions of Parasympathetic Stimulants and Anti (19) & (11) EP 1 938 839 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 45/06 (2006.01) A61K 31/4178 (2006.01) 19.08.2009 Bulletin 2009/34 A61P 27/10 (2006.01) (21) Application number: 06026169.0 (22) Date of filing: 18.12.2006 (54) Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie Compositions ophtalmiques de stimulants parasympathiques et anti-inflammatoires pour le traitement de la presbytie (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR WO-A-00/06135 US-A- 5 488 050 HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI US-B1- 6 273 092 SK TR • DATABASE BIOSIS [Online] BIOSCIENCES (43) Date of publication of application: INFORMATION SERVICE, PHILADELPHIA, PA, 02.07.2008 Bulletin 2008/27 US; 2002, OSTRIN L A ET AL: "Pilocarpine Stimulated Accommodation in Humans." (73) Proprietor: Benozzi, Jorge Luis XP002433091 Database accession no. Buenos Aires (AR) PREV200300154537 & ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, (72) Inventor: Benozzi, Jorge Luis vol. 2002, 2002, page Abstract No. 2317, ANNUAL Buenos Aires (AR) MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; (74) Representative: Minoja, Fabrizio FORT LAUDERDALE, FLORIDA, USA; MAY 05-10, Bianchetti Bracco Minoja S.r.l. 2002 Via Plinio, 63 20129 Milano (IT) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 938 839 B1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 938 839 B1 2 Description domethacin. [0012] Therefore, the present invention relates to [0001] The present invention relates to ophthalmic ophtalmic compositions comprising combinations of par- compositions comprising parasympathetic stimulants asympathomimetics and non-steroidal anti-inflammato- and non-steroidal anti-inflammatories for use in the treat- 5 ries for the treatment of presbyopia. ment of presbyopia, [0013] The parasympathomimetics present in the combinations of the invention act on the contraction/re- PRIOR ART laxation strength of the ciliary muscle thus keeping ac- commodation levels stable, while NSAIDs preserve such [0002] Presbyopia, a defect in accomodation, has tra- 10 action in time, preventing those physiological degenera- ditionally been treated with the use of corrective lens. tions typically occurring in time with presbyopic subjects. [0003] In recent years, surgery methods such as scle- The combinations of the invention prevent any histolog- ral expansion band, anterior ciliary sclerotomy, mulfiifo- ical and physical alterations (fibrosis and rigidity) in the cal intraocular lenses or laser ablation of sclera retrolim- ciliary muscle-zonula complex. bare (U.S. Pat. Nos. 6263879 and 6258082) have been 15 [0014] The present invention provides successful, sta- suggested to correct presbyopia. All of such techniques ble results in emmetropic and hypermetropic patients for are, however, controversial, as they do not solve the me- at least five years; on the other hand, the invention is chanical problem of accommodation (Mathews S., Scle- unsuccessful when shape modification of the lens is pre- ral Expansion Surgery does not Restore Accommodation vented by its rigidity. in Human Presbyopia. Ophthalmology 1999; 106: 20 [0015] More particularly, the present invention relates 873-877). to ophthalmic compositions of pilocarpine and a NSAID [0004] Publications concerning the treatment of pres- for use in the treatment of presbyopia. byopia do not take into account such mechanism and [0016] According to a preferred aspect of the invention, aim at a surgical correction of near vision. pilocarpine is in form of its hydrochloride and the NSAID [0005] Lin-Kadambi suggest sympathetic and para- 25 is diclofenac sodium. sympathetic stimulation with adrenergic and cholinergic [0017] The compositions of the invention will contain drugs to pharmacologically assist stabilization of the sur- the parasympathomimetic agent in amounts ranging gical results. Pharmacological treatment to treat accom- from 0.5% to 4% and the NSAID in amounts ranging from modation in man has been reported in previous articles. 0.01 mg. to 0.1 mg. [0006] According to Rosenfield, treatment with an al- 30 [0018] According to a preferred aspect of the invention, pha-adrenergic antagonist induced an increase in ac- the compositions will contain pilocarpine hydrochloride commodative amplitude of 1.5 D. Said action, however, in concentrations ranging from 1% to 2% and diclofenac only lasts two hours (Rosenfield M. The influence of Al- sodium in amounts ranging from 0.1% to 0.5%. pha-adrenergic-agents on tonic accommodation. Cur- [0019] The ophthalmic compositions will be suitably rent Eye Research, vol. 9, 3, 1990, pp. 267-272). 35 formulated for the topical administration, according to [0007] According to Nyberg, van Alphen et al., therapy well known procedure and techniques, such as those de- with alpha-adrenergic-agents was not satisfactory in scribed in "Remington’s Pharmaceutical Handbook", presbyopic patients. 18th edition (June 1995), Mack Publishing Co., N.Y., [0008] Nolan (U.S. Pat. No. 6,273,092) reports that USA, using conventional additives well known in the topical application of acetylcholine and physostygmine 40 pharmaceutical technique. Example of said additives are to presbyopic patient gives poor results and does not isotonic agents, such as propylene glycol, sodium chlo- solve blurred distant vision. ride, potassium chloride, glycerine, sorbitol, mannitol, and the like; buffers, such as boric, phosphoric, acetic, DISCLOSURE OF THE INVENTION carbonic, citric acids, and the like; stabilizers, such as 45 ethylenediaminetetraacetic acids, sodium hydrogen sul- [0009] The present invention relates to the pharmaco- phite, and the like; pH agents, such as citric, phosphoric, logical treatment of presbyopia, without surgical interven- hydrochloric, acetic acids, sodium or potassium hydrox- tion. ide, sodium carbonate or bicarbonate, and the like; sol- [0010] It has in fact been found that alterations of visual ubilizers, such as polysorbate, polyethylene glycol, pro- accommodation can be treated by stimulating the sym- 50 pylene glycol, macrogol 4000, and the like; thickening pathetic innervation which induces accommodation for and dispersing agents, such as cellulose derivatives, so- near vision by use of parasympathomimetics and that dium alginate, polyvinyl alcohol, carboxyvinylpolymer, said results can be maintained in time by treatment with polyvinyl pyrrolidone, and the like. non-steroidal anti-inflammatories (NSAIDs). [0020] The results of the pharmacological experimen- [0011] According to the invention, non-steroidal anti- 55 tation with the compositions of the invention are reported inflammatories can be selected from the group consisting the following. of diclofenac, ketorolac, bromfenac, flurbiprofen, supro- fen, pranoprofen, oxyphenbutazone, bendazac, in- 2 3 EP 1 938 839 B1 4 Materials and Methods plasty was carried out by shooting in 360° spots in the iris constrictor muscle. The laser intensity and [0021] 100 Presbiopic patients of both sexes, of age the size of the spot, were adapted to the intensity of 40 to 65, were treated with the compositions of the in- iris pigmentation. vention. Exclusion criteria concerned patients with myo- 5 • Topical treatment was modified in case of conjunc- pia or astigmatism higher than 1 dioptre, and hyper- tiva inflammation. metropia greater than 3 dioptres as well as those with • When ocular tension was not ideal, hypotensive corneal, lens and vitreous opacitis, and chronic general medication was modified prior to presbyopia treat- pathologies. ment. [0022] 4 Different groups of presbyopic population 10 • Orthoptic treatment was corrected in case of patient were differentiated: astenopia. • Treatment was suspended in case of intolerance to Group 1: Pure presbyopics medication. Group 2: Presbyopics with hypermetropia Group 3: Presbyopics with phorias 15 RESULTS AND CONCLUSIONS Group 4: Presbyopics with glaucoma [0030] [0023] Patients of all groups were treated with eye drops of different concentrations and combinations of 100 Patients were treated: 2 patients showed intol- medicaments acting on the ocular sympathetic innerva- 20 erance to pilocarpine hydrochloride (diarrhoea and tion. dyspepsia), 2 patients (presbyopics with hyper- [0024] Pure presbyopic patients (Group 1) were topi- metropia) did not obtain the desired improvement in cally treated with 1% pilocarpine hydrochloride + 0.5% visual sharpness. diclofenac sodium, at 6 hr intervals during the daily hours; 10 patients have been under treatment for 6 years treatment was suspended at night. 25 20 patients have been under treatment for 5 years [0025] Presbyopics with hypermetropia (Group 2) 30 patients have been under treatment for 4 years were topically treated with 2% pilocarpine hydrochloride 40 patients have been under treatment for 3 years + 0.5% diclofenac sodium, at 6 hr intervals during the 80 patients have been
Load more

Recommended publications
  • Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic
    Sys Rev Pharm 2020; 11(5): 464 468 A multifaceted review journal in the field of pharmacy E-ISSN 0976-2779 P-ISSN 0975-8453 Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic Agus Purnomo1, Arya Pradana Wicaksono2, Dodit Hendrawan2, Muhammad Thohawi Elziyad Purnama3* 1Department of Veterinary Surgery and Radiology, Faculty of Veterinary Medicine, Universitas Gadjah Mada, DI Yogyakarta, 55281, Indonesia 2Postgraduate Studies, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia 3Department of Veterinary Anatomy, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia *Corresponding author E-mail: [email protected] Article History: Submitted: 26.02.2020 Revised: 16.04.2020 Accepted: 21.05.2020 ABSTRACT This study aimed to evaluate the efficacy of flunixin, ketoprofen and multiple range test. The results showed a significant alleviation in all phenylbutazone on serum biochemistry, plasma catecholamines and observed variables on Day 13, although the use of various NSAIDs serum cortisol in Delman horses with mild colic. During the study showed no significant difference. period, 32 horses were evaluated due to mild colic. Flunixin, Keywords: serum biochemical, catecholamine, cortisol, colic, NSAIDs ketoprofen, and phenylbutazone were administered intravenously at Correspondence: the recommended dose rates of 1.0; 2.2 and 4.4 mg/kg, respectively. Muhammad Thohawi Elziyad Purnama Administration of the NSAIDs commenced on Day 1 and continued Department of Veterinary Anatomy, Faculty of Veterinary Medicine, every 12 h for 12 days. Blood samples collected between days 2, 5, 9 Universitas Airlangga, Surabaya, 60115, Indonesia and 13 to evaluate AST, ALP, GGT, creatinine, urea, epinephrine, E-mail: [email protected] norepinephrine, and cortisol level.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANALYSIS IN MILK BY QUECHERS AND LC-MS: LOW AND HIGH RESOLUTION DETECTION AND CONFIRMATION APPROACHES A. Rúbies1, L. Guo2, I. Beguiristain1, F. Centrich1, M. Granados2 1. Laboratori Agència de Salut Pública de Barcelona, 2. Departament de Química Analítica - Universitat de Barcelona. * INTRODUCTION NON-STEROIDAL ANTI-INFLAMATORY DRUGS (NSAIDs) Non-steroidal anti-inflammatory drugs (NSAIDs) are used as anti-inflammatory, analgesic and OXICAMS ANTHRANILIC ACID DERIVATIVES ACETIC ACID antipyretic drugs in medicine and veterinary. Their action mechanism is based on the blocking of PROPIONIC ACID DERIVATIVES DERIVATIVES the biosynthesis of prostaglandins. NSAIDs are highly effective and extensively used, but they have some adverse side effects, such as hepatotoxicity, renal disorders or allergic reactions. In the European Union, to assure food safety and protect consumers, maximum residue limits have been established for some authorised NSAIDs in food products. Therefore, high throughput and reliable analytical methodology is required for the effective control of NSAIDs in food from animal Flufenamic acid origin. Liquid chromatography (LC) coupled to mass spectrometry (MS) is currently the technique of choice in confirmatory analysis of NSAIDs residues. We present a new method for the determination of representative NSAIDs in milk based on QuEChERS methodology, LC-MS/MS and UHPLC-HRMS. Meloxicam Ketoprofen Diclofenac EU Maximum Residue Limits (MRLs) Recommended NSAIDs concentrations for NSAIDs in milk.
    [Show full text]
  • In 1977 a Conclusion of the National Association of State Racing Commissioners Veterinary-Chemist Advisory Board Concluded That
    Lawrence R. Soma, VMD, University of Pennsylvania, School of Veterinary Medicine. This review was undertaken at the request of the Racing Medication and Testing Consortium, Medication Advisory Committee. Review: The use of phenylbutazone in the horse This review presents a brief historical prospective of the genesis of regulated medication in the US racing industry of which the non-steroidal anti-inflammatory drug phenylbutazone (PBZ) is the focus. It presents some historical guide posts in the development of the current rules on the use on PBZ by racing jurisdictions in the US. Based on its prevalent use, PBZ still remains a focus of attention. The review examines the information presented in a number of different models used to determine the effects and duration of PBZ in the horse. They include naturally occurring lameness and reversible induced lameness models that directly examine the effects and duration of the administration of various doses of PBZ. The review also examines indirect plasma and tissue models studying the suppression of the release of arachidonic acid- derived mediators of inflammation. The majority of studies suggest an effect of PBZ at 24 hours at 4.4 mg/kg. This reflects and substantiates the opinion of many clinical veterinarians, many of whom will not perform a pre-purchase lameness examination unless the horse is shown to be free of NSAID. This remains the opinion of many Commission Veterinarians in that they wish to examine a horse pre-race without the possibility of a NSAID interfering with the examination and masking possible musculoskeletal conditions. Based on scientific studies, residual effects of PBZ remain at 24 hours following administration.
    [Show full text]
  • Can Cataract Be Prevented?
    Can cataract be JOHN J. HARDING prevented? Abstract The other major drawback of surgery is the risk of complications. In percentage terms the The feasibility of preventing cataract by risk of most complications is small, but given elimination of risk factors or by anti-cataract the enormous number of procedures - about 2 therapy is reviewed. Elimination of the major million per annum in both the United States and risk factors in Western countries would be India, for example - the overall number of even difficult, although it has potential in the serious complications is great. One developing world. Various approaches to drug complication, posterior capsular opacification therapy have been made but ran into (PCO), occurs in up to 50% of patients but in problems. The development of aldose 3 younger patients it affects almost 100%. In reductase inhibitors received by far the many of the countries with the greatest cataract greatest financial support but problems with toxicity were rapidly followed by the collapse problems the equipment to deal with this of the original hypothesis. The case of aspirin, complication is a rarity, a point which is ignored paracetamol and ibuprofen built up more by those advocating greater use of the latest slowly with no encouragement from the Western surgical techniques in developing pharmaceutical industry. Positive results have countries.4 In Nepal the outcome of surgery been achieved in vitro, and in the prevention with intraocular lenses was no better than that of diabetic cataract in rats, as well as the without; and 50% of the impaired vision in identification of an association with a operated eyes was attributed to surgical protective effect against cataract in human complications including PCO.s patients.
    [Show full text]
  • Changes Highlighted Final Version Date of Issue: 23Rd December 2015
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2016 Section A Changed Classes/Guidelines: Changes Highlighted Final Version Date of issue: 23rd December 2015 1 A2B ANTIULCERANTS R1997r2 016 Combinations of specific antiulcerants with anti-infectives against Helicobacter pylori are classified according to the anti-ulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2. A2B1 H2 antagonists R2002 Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. A2B2 Acid Proton pump inhibitors R2003r2 016 Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. A2B3 Prostaglandin antiulcerants Includes misoprostol, enprostil. A2B4 Bismuth antiulcerants Includes combinations with antacids. A2B9 All other antiulcerants R2002r2 016 Includes all other products specifically stated to be antiulcerants even when containing antispasmodics (see A3). Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. Included are, eg carbenoxolone, gefarnate, pirenzepine, proglumide, sucralfate and sofalcone. Herbal combinations are classified in A2C. In Japan, Korea and Taiwan only, sulpiride and other psycholeptics indicated for ulcer use are also included in this group, whilst in all other countries, these compounds are classified in N5A9. Products containing rebamipide for gastric mucosal protection are classified here. Products containing rebamipide and indicated for dry eye are classified in S1K9. A2C OTHER STOMACH DISORDER PREPARATIONS R1994 Includes herbal preparations and also plain alginic acid. Combinations of antacids with alginic acid are in A2A1. 2 A4 ANTIEMETICS AND ANTINAUSEANTS A4A ANTIEMETICS AND ANTINAUSEANTS R1996 Products indicated for vertigo and Meniere's disease are classified in N7C. Gastroprokinetics are classified in A3F.
    [Show full text]
  • University of Groningen Reflections on Flurbiprofen Eyedrops Van Sorge
    University of Groningen Reflections on flurbiprofen eyedrops van Sorge, Adriaan Alastair IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2002 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): van Sorge, A. A. (2002). Reflections on flurbiprofen eyedrops. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 REFLECTIONS ON FLURBIPROFEN EYEDROPS REFLECTIONS ON FLURBIPROFEN EYEDROPS RIJKSUNIVERSITEIT GRONINGEN REFLECTIONS ON FLURBIPROFEN EYEDROPS REFLECTIONS ON FLURBIPROFEN EYEDROPS PROEFSCHRIFT ter verkrijging van het doctoraat in de Wiskunde en Natuurwetenschappen aan de Rijksuniversiteit Groningen, op gezag van de Rector Magnificus, dr. F. Zwarts, in het openbaar te verdedigen op maandag 2 december 2002 om 14.15 uur door Adriaan Alastair van Sorge geboren op 28 oktober 1944 te New Rochelle, New York, USA PROMOTORES Prof.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Composition for Use in Treating and Preventing Inflammation Related Disorder
    (19) TZZ 54¥¥7A_T (11) EP 2 543 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.01.2013 Bulletin 2013/02 A61K 9/00 (2006.01) A61K 47/36 (2006.01) (21) Application number: 11173000.8 (22) Date of filing: 07.07.2011 (84) Designated Contracting States: (72) Inventor: Lin, Shyh-Shyan AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei (TW) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Becker Kurig Straus Designated Extension States: Bavariastrasse 7 BA ME 80336 München (DE) (71) Applicant: Holy Stone Healthcare Co.,Ltd. Taipei City (TW) (54) Composition for use in treating and preventing inflammation related disorder (57) The presentinvention isrelated to ause fortreat- ease, coeliac disease, conjunctivitis, otitis, allergic rhin- ing and preventing inflammation related disorder of a itis, gingivitis, aphthous ulcer, bronchitis, gastroesopha- composition containing a drug and hyaluronic acid (HA) geal reflux disease (GERD), esophagitis, gastritis, en- or HA mixture, whereas the HA or the HA mixture as a teritis, peptic ulcer, inflammatory bowel disease (IBD), delivery vehicle can be a formulation including at least Crohn’s Disease, irritable bowel syndrome (IBS), intes- two HAs having different average molecular weights. The tinal inflammation or allergy, urethritis, cystitis, vaginitis, composition has been demonstrated to be capable of proctitis, eosinophilic gastroenteritis, or rheumatoid ar- reducing the therapeutic dose of a drug on the treatment thritis. and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary dis- EP 2 543 357 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 543 357 A1 2 Description alleviate pain by counteracting the cyclooxygenase (COX) enzyme.
    [Show full text]
  • (Brufen®) Following the Removal of Impacted Third Molar Teeth
    Journal of the Dental Association of SA 38, 739-742 The effect of Ibuprofen (Brufen®) following the removal of impacted third molar teeth Garwood, A.J., Lownie, J.F., Cleaton-Jones, P.E. and Butz, S.J. Division of Maxillo-facial and Oral Surgery, University of the Witwatersrand, and MRC/University of the Wit- watersrand Dental Research Institute, Johannesburg Key words: analgesics; ibuprofen; oral surgery. SUMMARY OPSOMMING Pain, swelling and trismus are common features after the Pyn, swelsel en trismus kom dikwels voor na die chirur- surgical removal of impacted third molar teeth. The pur­ giese verwydering van geimpakteerde derde molare. Die pose of this study was to compare the efficacy and side doel van hierdie ondersoek was om die doeltreffendheid effects o f ibuprofen (Brufen®), a non-steroidal anti-in­ en newe-effekte van ibuprofen (Brufen®), ’n nie-steroi'ed flammatory agent, with that of a control analgesic in a anti-inflammatoriese middel, te vergelyk met die van 'n double blind clinical trial following the removal of im­ kontrole-pyndoder, in ’n dubbel-blinde toets na die chi- pacted third molar teeth. The operative procedure was rurgiese verwydering van bogenoemde tande. Die opera- carried out on 100 patients by one surgeon using a stan­ tiewe prosedure is op 100 pasiente deur een chirurg dardised surgical technique while the survey was carried onderneem, ’n gestandaardiseerde chirurgiese tegniek is out by an independent observer. The results showed that gebruik en die ondersoek is deur ’n onafhanklike waar- ibuprofen compared favourably with the control anal­ nemer gedoen. Die resultate het getoon dat ibuprofen gesic, both o f which produced acceptable analgesia, al­ goed vergelyk met die kontrolepyndoder.
    [Show full text]
  • Pharmaceutical Compositions Containing Non-Steroidal Anti-Inflammatory Drugs
    Europaisches Patentamt J European Patent Office © Publication number: 0 259 047 Office europeen des brevets A1 s EUROPEAN PATENT APPLICATION © Application number: 87307246.6 © int. CIA A61K 45/06 A61 , K 31/60 , A61K 31/405, © Date of filing: 17.0&87 //(A61 K31/60,31 :1 85),(A61 K31/- 405,31:185) ® Priority: 18.08.86 GB 8620073 © Applicant: DELANDALE LABORATORIES LIMITED © Date of publication of application: Delandale House 37 Old Dover Road 09.03.88 Bulletin 88/10 Canterbury Kent CT1 3JF(GB) © Designated Contracting States: @ inventor: Trigger, David John AT BE CH DE ES FR GB GR IT LI LU NL SE 74 Mountbatten Way Brabourne Lees Ashford Kent TN25 6PU(GB) © Representative: Paget, Hugh Charles Edward etal MEWBURN ELUS & CO. 2/3 Cursitor Street London EC4A 1BQ(GB) © Pharmaceutical compositions containing non-steroidal anti-Inflammatory drugs. © A pharmaceutical composition for treating an inflammatory condition contains a non-steroidal anti-inflam- matory drug (NSAID) and a physiologically acceptable aromatic hydroxysulphonic acid. The two components may be for simultaneousr separate or sequential use. Administration of the two components, for example of aspirin with ethamsylate, reduces the damage which the NSAID does to the gastrointestinal tract while having no deleterious effect on the anti-inflammatory activity. s in cm Q. LU Xerox Copy Centre 0 259 047 PHARMACEUTICAL COMPOSITIONS CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS The present invention relates to pharmaceutical compositions containing aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). The non-steroidal anti-inflammatory drugs are a group of compounds which inhibit the biosynthesis of prostaglandins.
    [Show full text]
  • 2018/CM05 Horse: CHIRO D' ANDRUER
    DECISION of the FEI TRIBUNAL dated 23 October 2018 Positive Controlled Medication Case No.: 2018/CM05 Horse: CHIRO D’ ANDRUERE FEI Passport No: 103VS23/UAE Person Responsible/NF/ID: Thani Mohd Ahmad AL MARRI/UAE/10113330 Event/ID: CEI1* 80 – Dubai (UAE)/2018_CI_0523_E_S_02_01 Date: 1 February 2018 Prohibited Substances: Phenylbutazone, Oxyphenbutazone, Dexamethasone and Diclofenac. I. COMPOSITION OF PANEL Mr. Henrik Arle (FIN), one member panel II. SUMMARY OF THE FACTS 1. Memorandum of case: By Legal Department. 2. Summary information provided by Person Responsible (PR): The FEI Tribunal duly took into consideration all evidence, submissions and documents presented in the case file, as also made available by and to the PR. 3. Oral hearing: none. III. DESCRIPTION OF THE CASE FROM THE LEGAL VIEWPOINT 1. Articles of the Statutes/Regulations which are applicable: Statutes 23rd edition, effective 29 April 2015 (“Statutes”), Arts. 1.4, 38 and 39. General Regulations, 23rd edition, 1 January 2009, updates effective 1 January 2018, Arts. 118, 143.1, 161, 168 and 169 (“GRs”). Page 1 of 11 Internal Regulations of the FEI Tribunal, 2nd edition, 1 January 2012, and Internal Regulations of the FEI Tribunal, 3rd Edition, 2 March 2018 (Part I – 3.) (“IRs”). FEI Equine Anti-Doping and Controlled Medication Regulations ("EADCMRs"), 2nd edition, effective 1 January 2018. FEI Controlled Medication Regulations ("ECM Rules"), 2nd edition, effective 1 January 2018. Veterinary Regulations (“VRs”), 14th edition 2018, effective 1 January 2018, Art. 1055 and seq. FEI Code of Conduct for the Welfare of the Horse. 2. Person Responsible: Mr. Thani Mohd Ahmad Al Marri. 3.
    [Show full text]
  • Methods Research Report: Empirical Evidence of Associations Between
    Methods Research Report Empirical Evidence of Associations Between Trial Quality and Effect Size Methods Research Report Empirical Evidence of Associations Between Trial Quality and Effect Size Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 http://www.ahrq.gov Contract No. HHSA 290-2007-10062-I Prepared by: Southern California Evidence-based Practice Center Santa Monica, CA Investigators: Susanne Hempel, Ph.D. Marika J. Suttorp, M.S. Jeremy N.V. Miles, Ph.D. Zhen Wang, M.S. Margaret Maglione, M.P.P. Sally Morton, Ph.D. Breanne Johnsen, B.A. Diane Valentine, J.D. Paul G. Shekelle, M.D., Ph.D. AHRQ Publication No. 11-EHC045-EF June 2011 This report is based on research conducted by the Southern California Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10062-I). The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]